CAR--话题@MedSci

#CAR-#

459篇内容 | 2582人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1781412, encodeId=dc581e81412a2, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, objectType=article, longId=206908, objectId=2d6520690891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6520690891, replyNumber=0, likeNumber=66, createdTime=2021-09-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6520690891, moduleTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6520690891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781425, encodeId=114e1e81425c1, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=全球第五款CAR-T疗法获FDA批准上市，靶向BCMA, objectType=article, longId=209485, objectId=5249209485d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5249209485d2, replyNumber=0, likeNumber=85, createdTime=2021-11-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5249209485d2, moduleTitle=全球第五款CAR-T疗法获FDA批准上市，靶向BCMA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5249209485d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781442, encodeId=210c1e8144283, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=中国第二款CAR-T产品获批，同质化竞争加剧来临, objectType=article, longId=216655, objectId=427b2166553e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=427b2166553e, replyNumber=0, likeNumber=66, createdTime=2022-05-31, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=427b2166553e, moduleTitle=中国第二款CAR-T产品获批，同质化竞争加剧来临, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=427b2166553e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781393, encodeId=b09f1e8139333, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=金斯瑞子公司传奇再次公布CAR-T临床数据，总缓解率达97%，研究者期待用于更前线治疗, objectType=article, longId=204239, objectId=c17020423988, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c17020423988, replyNumber=0, likeNumber=71, createdTime=2021-06-22, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c17020423988, moduleTitle=金斯瑞子公司传奇再次公布CAR-T临床数据，总缓解率达97%，研究者期待用于更前线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c17020423988)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781419, encodeId=2a411e8141922, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=NICE：欧洲套细胞淋巴瘤患者将从CAR-T细胞疗法中全面受益！, objectType=article, longId=207682, objectId=34c920e68265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34c920e68265, replyNumber=0, likeNumber=85, createdTime=2021-10-14, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34c920e68265, moduleTitle=NICE：欧洲套细胞淋巴瘤患者将从CAR-T细胞疗法中全面受益！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34c920e68265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781410, encodeId=310a1e81410b6, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤, objectType=article, longId=206689, objectId=8a6220668996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a6220668996, replyNumber=0, likeNumber=64, createdTime=2022-01-14, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a6220668996, moduleTitle=欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a6220668996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781446, encodeId=16621e814465e, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=基因编辑的未来遭质疑，因严重安全问题，FDA暂停基于基因编辑的CAR-T临床试验, objectType=article, longId=218384, objectId=d69e2183841b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d69e2183841b, replyNumber=0, likeNumber=70, createdTime=2021-11-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d69e2183841b, moduleTitle=基因编辑的未来遭质疑，因严重安全问题，FDA暂停基于基因编辑的CAR-T临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d69e2183841b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781434, encodeId=8ea31e81434bb, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature Communications：来自肠道细菌的抗癌利器，通过抗肿瘤代谢物增强CAR-T效果, objectType=article, longId=214102, objectId=5084214102e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5084214102e5, replyNumber=0, likeNumber=72, createdTime=2022-03-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5084214102e5, moduleTitle=Nature Communications：来自肠道细菌的抗癌利器，通过抗肿瘤代谢物增强CAR-T效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5084214102e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781432, encodeId=04f51e8143276, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择, objectType=article, longId=212792, objectId=f30c212e92da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f30c212e92da, replyNumber=0, likeNumber=82, createdTime=2022-04-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f30c212e92da, moduleTitle=Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f30c212e92da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Oncternal Therapeutics与卡罗林斯卡研究所合作开发靶向ROR1的CAR-T和CAR-NK细胞疗法, objectType=article, longId=205517, objectId=6a4020551e01, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a4020551e01, replyNumber=0, likeNumber=72, createdTime=2021-12-18, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a4020551e01, moduleTitle=Oncternal Therapeutics与卡罗林斯卡研究所合作开发靶向ROR1的CAR-T和CAR-NK细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a4020551e01)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781413, encodeId=54841e81413ed, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Commun：多发性骨髓瘤患者中BCMA的双等位基因缺失引起CAR-T疗法耐药性的产生, objectType=article, longId=207031, objectId=34d520e0312e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34d520e0312e, replyNumber=0, likeNumber=66, createdTime=2021-05-03, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34d520e0312e, moduleTitle=Nat Commun：多发性骨髓瘤患者中BCMA的双等位基因缺失引起CAR-T疗法耐药性的产生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34d520e0312e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781429, encodeId=0e8f1e8142923, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果, objectType=article, longId=211106, objectId=51f721110637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51f721110637, replyNumber=0, likeNumber=75, createdTime=2022-02-24, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51f721110637, moduleTitle=NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51f721110637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781403, encodeId=39231e81403ff, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=**上市在即，国内CAR-T疗法如何定价？, objectType=article, longId=205922, objectId=1b6e205922b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b6e205922b3, replyNumber=0, likeNumber=50, createdTime=2021-04-21, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b6e205922b3, moduleTitle=**上市在即，国内CAR-T疗法如何定价？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b6e205922b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781411, encodeId=c4821e814115b, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=欧洲药品管理局接受加速审评传奇生物CAR-T疗法申请, objectType=article, longId=206717, objectId=53f5206e17b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53f5206e17b0, replyNumber=0, likeNumber=75, createdTime=2021-02-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53f5206e17b0, moduleTitle=欧洲药品管理局接受加速审评传奇生物CAR-T疗法申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53f5206e17b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781408, encodeId=5fa61e8140810, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Commun：GD2-B7H3 SynNotch CAR-T在转移性神经母细胞瘤中的临床前评估, objectType=article, longId=206277, objectId=56be2062e7d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56be2062e7d0, replyNumber=0, likeNumber=69, createdTime=2021-02-21, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56be2062e7d0, moduleTitle=Nat Commun：GD2-B7H3 SynNotch CAR-T在转移性神经母细胞瘤中的临床前评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56be2062e7d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781405, encodeId=d3991e8140503, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Clin Cancer Res：CEACAM7是CAR-T细胞治疗胰腺导管腺癌的有效靶点, objectType=article, longId=206165, objectId=19d8206165d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19d8206165d9, replyNumber=0, likeNumber=90, createdTime=2021-08-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19d8206165d9, moduleTitle=Clin Cancer Res：CEACAM7是CAR-T细胞治疗胰腺导管腺癌的有效靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19d8206165d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781397, encodeId=7df71e8139747, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=国内自主CAR-T疗法被纳入突破性治疗品种, objectType=article, longId=204865, objectId=d3fb20486556, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3fb20486556, replyNumber=0, likeNumber=73, createdTime=2021-09-01, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3fb20486556, moduleTitle=国内自主CAR-T疗法被纳入突破性治疗品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3fb20486556)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781399, encodeId=c2fc1e813999d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Cell Chem Biol：光敏CAR-T细胞有望成为自身免疫性疾病的通用治疗平台, objectType=article, longId=205280, objectId=149820528009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=149820528009, replyNumber=0, likeNumber=64, createdTime=2021-02-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=149820528009, moduleTitle=Cell Chem Biol：光敏CAR-T细胞有望成为自身免疫性疾病的通用治疗平台, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=149820528009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781394, encodeId=29391e813943f, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=ASH 2020：亘喜生物BCMA/CD19双靶向CAR-T治疗复发或难治多发性骨髓瘤首次人体治疗数据惊艳, objectType=article, longId=204260, objectId=d025204260e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d025204260e3, replyNumber=0, likeNumber=73, createdTime=2021-01-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d025204260e3, moduleTitle=ASH 2020：亘喜生物BCMA/CD19双靶向CAR-T治疗复发或难治多发性骨髓瘤首次人体治疗数据惊艳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d025204260e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781398, encodeId=9f821e813989d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Lenzilumab预防或治疗与CAR-T细胞疗法相关细胞因子风暴和神经毒性, objectType=article, longId=204991, objectId=a8c8204991ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8c8204991ff, replyNumber=0, likeNumber=110, createdTime=2021-04-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8c8204991ff, moduleTitle=Lenzilumab预防或治疗与CAR-T细胞疗法相关细胞因子风暴和神经毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8c8204991ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAR-

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！

2021-09-07

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

全球第五款CAR-T疗法获FDA批准上市，靶向BCMA

2021-11-02

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

中国第二款CAR-T产品获批，同质化竞争加剧来临

2022-05-31

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

金斯瑞子公司传奇再次公布CAR-T临床数据，总缓解率达97%，研究者期待用于更前线治疗

2021-06-22

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

NICE：欧洲套细胞淋巴瘤患者将从CAR-T细胞疗法中全面受益！

2021-10-14

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤

2022-01-14

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

基因编辑的未来遭质疑，因严重安全问题，FDA暂停基于基因编辑的CAR-T临床试验

2021-11-23

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nature Communications：来自肠道细菌的抗癌利器，通过抗肿瘤代谢物增强CAR-T效果

2022-03-02

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择

2022-04-08

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Oncternal Therapeutics与卡罗林斯卡研究所合作开发靶向ROR1的CAR-T和CAR-NK细胞疗法

2021-12-18

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Commun：多发性骨髓瘤患者中BCMA的双等位基因缺失引起CAR-T疗法耐药性的产生

2021-05-03

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果

2022-02-24

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

**上市在即，国内CAR-T疗法如何定价？

2021-04-21

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

欧洲药品管理局接受加速审评传奇生物CAR-T疗法申请

2021-02-11

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Commun：GD2-B7H3 SynNotch CAR-T在转移性神经母细胞瘤中的临床前评估

2021-02-21

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Clin Cancer Res：CEACAM7是CAR-T细胞治疗胰腺导管腺癌的有效靶点

2021-08-17

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

国内自主CAR-T疗法被纳入突破性治疗品种

2021-09-01

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Cell Chem Biol：光敏CAR-T细胞有望成为自身免疫性疾病的通用治疗平台

2021-02-07

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

ASH 2020：亘喜生物BCMA/CD19双靶向CAR-T治疗复发或难治多发性骨髓瘤首次人体治疗数据惊艳

2021-01-17

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Lenzilumab预防或治疗与CAR-T细胞疗法相关细胞因子风暴和神经毒性

2021-04-29

科室
- - 订阅+
  - 更多科室
工具
服务